Cipla Ltd (CIPLA) — Announcement | 28 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
USFDA classifies Invagen facility inspection as Voluntary Action Indicated
💡 Investor Takeaway
The VAI classification signals minor regulatory deviations requiring follow-up but does not indicate product recalls or supply disruptions.

Cipla disclosed that the USFDA classified its Invagen manufacturing facility inspection in Central Islip, NY as Voluntary Action Indicated (VAI) on August 28, 2026, following a July 13-17 inspection. This regulatory update pertains to its wholly owned subsidiary and impacts compliance standing in the US market.

📄 View Original Announcement (PDF)

About Cipla Ltd (CIPLA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹1,14,390.9 Cr P/E: 33.9 ROE: 9.8% ROCE: 13.2% Div Yield: 0.92%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day